RESUMO
Forty-eight cases of canine mammary cancer were investigated to evaluate the immunohistochemical distribution of the γ2 chain of laminin-332. Tumor cells were compared to a pool of normal mammary tissues using quantitative RT-PCR. The western blot was performed in eight tumor samples as complementary test to evaluate protein integrity. Immunohistochemistry experiments showed negative, focal, and weak expression of laminin-332 γ2 in tumors with the worst prognosis. Quantitative PCR revealed downregulation of the gene in 27 (56.2 percent) of the animals. Out of the 16 dogs with γ2 chain overexpression, seven were still alive. The western blot results showed bands generation of 36, 50, and 98kDa, suggesting degradation of laminin-332 γ2 in malignant tumors. The results suggest that, in the future, low expression and/or degradation of laminin-332 γ2 chain in canine mammary tumors may be used as an indicator of malignant potential. However, further studies are necessary to corroborate these results.
Para avaliar a expressão imunoistoquímica da cadeia γ 2 da laminina-332, foram investigados 48 casos de câncer mamário canino. Comparou-se, por RT-PCR, a expressão gênica nas células tumorais com um pool de tecido mamário. Como teste complementar, em oito amostras tumorais, realizou-se western blot para avaliar a integridade da proteína laminina-332 γ 2. A imunoistoquímica demonstrou expressão negativa, focal e fraca da laminina-332 γ 2 nos tumores com pior prognóstico. A RT-PCR quantitativa revelou a baixa expressão do gene em 27 (56,2 por cento) dos animais. Das 16 cadelas com superexpressão da cadeia γ 2, sete ainda estavam vivas no final do estudo. O resultado do western blot mostrou bandas de 36, 50 e 98kDa, sugerindo uma degradação da laminina-332 γ 2 em tumores malignos. Os resultados sugerem que, no futuro, a baixa expressão e/ou degradação da laminina-332 γ 2 nos tumores mamários caninos podem ser utilizadas como indicadores de potencial maligno. No entanto, mais estudos são necessários para confirmar estes resultados.
Assuntos
Animais , Cães/classificação , Neoplasias da Mama/patologia , Imuno-Histoquímica , Laminina/síntese químicaRESUMO
AIMS: Annexin A1 (ANXA1) is a soluble cytoplasmic protein, moving to membranes when calcium levels are elevated. ANXA1 has also been shown to move to the nucleus or outside the cells, depending on tyrosine-kinase signalling, thus interfering in cytoskeletal organization and cell differentiation, mostly in inflammatory and neoplastic processes. The aim was to investigate subcellular patterns of immunohistochemical expression of ANXA1 in neoplastic and non-neoplastic samples from patients with laryngeal squamous cell carcinomas (LSCC), to elucidate the role of ANXA1 in laryngeal carcinogenesis. METHODS AND RESULTS: Serial analysis of gene expression experiments detected reduced expression of ANXA1 gene in LSCC compared with the corresponding non-neoplastic margins. Quantitative polymerase chain reaction confirmed ANXA1 low expression in 15 LSCC and eight matched normal samples. Thus, we investigated subcellular patterns of immunohistochemical expression of ANXA1 in 241 paraffin-embedded samples from 95 patients with LSCC. The results showed ANXA1 down-regulation in dysplastic, tumourous and metastatic lesions and provided evidence for the progressive migration of ANXA1 from the nucleus towards the membrane during laryngeal tumorigenesis. CONCLUSIONS: ANXA1 dysregulation was observed early in laryngeal carcinogenesis, in intra-epithelial neoplasms; it was not found related to prognostic parameters, such as nodal metastases.
